A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

No Carolina / New York

Riverside Medical Center Performs 1st In-Patient Use of Biomaterial-Based HydroPICC® Dual Lumen Catheter

What To Know

  • Approximately 85% of hospital patients in the United States receive a vascular access device and many of those patients encounter a vascular access-related complication caused by the use of a polyurethane catheter that can delay their treatment and sometimes lead to infections or even death.
  • The unique, patented biomaterial used by Access Vascular in its suite of vascular access devices is designed to avoid these complications and has demonstrated a significant reduction in complications such as occlusions, deep vein thrombosis and phlebitis in recent studies.

Access Vascular, Inc. (AVI) today announced that Riverside Medical Center, located just outside the Chicago area, was the first in the nation to use its HydroPICC® Dual-Lumen catheter in a patient.

Made from a proprietary hydrophilic biomaterial featuring MIMIX™ technology, the device was inserted by Dr. Howard Roth at the level-two trauma Magnet® hospital in a patient experiencing complications with their existing polyurethane catheter.

Approximately 85% of hospital patients in the United States receive a vascular access device and many of those patients encounter a vascular access-related complication caused by the use of a polyurethane catheter that can delay their treatment and sometimes lead to infections or even death. PICC and midline complications cost more than $4.5 billion dollars annually and can cost a single, large hospital more than $3 million dollars per year.

“We frequently encounter patients with vascular access complications or polyurethane catheters that need to be replaced and are pleased to have a biomaterial alternative,” said Dr. Roth. “We want our patients to focus on getting healthier, and by reducing complications associated with their vascular access device, we can accelerate their treatment and eventual recovery.”

The unique, patented biomaterial used by Access Vascular in its suite of vascular access devices is designed to avoid these complications and has demonstrated a significant reduction in complications such as occlusions, deep vein thrombosis and phlebitis in recent studies.

“It is a tremendous validation to see our dual-lumen device helping patients,” said James Biggins, CEO of Access Vascular. “Putting this device in the hands of clinicians will help speed treatment and healing while also reducing the overall cost of care for health systems and insurers.”

The HydroPICC Dual-Lumen is a 5 French catheter available in multiple kit configurations. It will be made available over the coming weeks as the newest addition to the expanding family of AVI vascular access devices. AVI plans to continue expansion of its portfolio by adding more peripheral intravenous and central line options.

To learn more about AVI, its family of biomaterial-based catheters or to request the HydroPICC Dual-Lumen, please visit https://www.accessvascularinc.com/.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The study is designed to assess the clinical utility and workflow benefits of Swoop® system images acquired at infusion centers and clinics to help physicians detect amyloid-related imaging abnormalities (ARIA) in Alzheimer’s patients receiving amyloid-targeting therapy at the times specified in the labeling (before the fifth, seventh, and fourteenth infusions).
“Tom and I have more than 50 years of experience,” Harp adds. “The decision to found Polymer Medical was done after careful consideration of the landscape and market opportunity; we will raise the level of competition and quality for customers.” Polymer Medical is located in a newly refurbished plant is at 168 Thorn Ave., Orchard Park, N.Y.
The RWE Program will expand Summus Laser's Class IV Laser Therapy research to generate validated and statistically significant datasets that will be used to enhance patient care, outcomes, and to further product innovations.
Details of the session: Polaroid Therapeutics & Avery Dennison Medical: How the power of partnership brings a novel approach to antimicrobial wound dressings.
SABIC advises the project was initiated together with the dialysis department at Jessa Hospital, one of the largest non-university medical cluster in the Limburg region of Flanders, Belgium.

By using this website you agree to accept Medical Device News Magazine Privacy Policy